Udayan MD - NextCure Senior Development
| NXTC Stock | USD 1.19 0.10 7.75% |
Executive
Udayan MD is Senior Development of NextCure
| Address | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Phone | 240 399 4900 |
| Web | https://www.nextcure.com |
NextCure Management Efficiency
The company has return on total asset (ROA) of (0.3109) % which means that it has lost $0.3109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5475) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, NextCure's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 200.8 M, whereas Net Tangible Assets are forecasted to decline to about 173.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard Colonno | Assembly Biosciences | 74 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Anuj MD | Assembly Biosciences | 46 | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Moses Makunje | Nuvation Bio | 45 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.31 |
NextCure Leadership Team
Elected by the shareholders, the NextCure's board of directors comprises two types of representatives: NextCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NextCure. The board's role is to monitor NextCure's management team and ensure that shareholders' interests are well served. NextCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NextCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Steven CPA, Chief Officer | ||
| Sebastien Maloveste, Senior Development | ||
| Sourav Kundu, Senior Manufacturing | ||
| Kevin Shaw, General Counsel | ||
| Michael MSBA, CEO, CoFounder | ||
| Lieping MD, CoFounder Board | ||
| Timothy Mayer, Chief Officer | ||
| MD FACP, Chief Officer | ||
| Udayan MD, Senior Development | ||
| Solomon Langermann, Chief Officer | ||
| Stacy Rollinger, Vice Resources |
NextCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NextCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (36.59 M) | ||||
| Shares Outstanding | 28.01 M | ||||
| Shares Owned By Insiders | 8.85 % | ||||
| Shares Owned By Institutions | 57.50 % | ||||
| Number Of Shares Shorted | 66.12 K | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 9.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.10) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.